Bc Platforms With Iqvia To Extend Data Analytics In Genomics

To Expand Data Analytics In Genomics Bc Platforms Collaborate With Bc platforms, a world leader in genomic data management and analytics, has closed a usd $15 million financing round alongside a new commercial collaboration with iqvia™. the round was led by iqvia in conjunction with debiopharm innovation fund and tesi, a finnish venture capital and private equity company. as part of the collaboration, iqvia. As part of the collaboration, iqvia and bc platforms plan to launch new data driven technologies, integrating complex clinical and genomic data, to benefit transformational research. iqvia and bc platforms have a shared vision to build a world leading analytics platform to enable the pharmaceutical industry’s advancement of precision medicine.

Bc Platforms With Iqvia To Extend Data Analytics In Genomics Bc platforms, a world leader in genomic data management and analytics, today announced that it has closed a usd $15 million financing round alongside a new commercial collaboration with iqvia (nyse: iqv). the round was led by iqvia in conjunction with debiopharm innovation fund and tesi, a finnish venture capital and private equity company. as part of the collaboration, iqvia and bc platforms. More immediately, bc platforms, of zurich, switzerland, will lend its technology to iqvia's e360 genomics, an integrated genomic clinical build of the established e360 data mining platform. this, the companies said, will support a federated genomic analytics network designed to safeguard patient privacy. “iqvia and bc platforms aim to combine genomic and clinical data assets around the world,” tero silvola, ceo at bc platforms, said. “iqvia´s e360™ genomics is built on patented techniques that allow us to build data access without compromising data privacy and security. together with iqvia´s deep healthcare expertise in managing and. Zurich, switzerland and boston, us — bc platforms, a world leader in genomic data management and analytics, today announced that it has closed a usd $15 million financing round alongside a new commercial collaboration with iqvia™ (nyse: iqv). the round was led by iqvia in conjunction with debiopharm innovation fund and tesi, a finnish venture capital and private equity company. as part […].